{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:28:20Z","timestamp":1770139700513,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rituximab is a novel chimeric monoclonal antibody that has established itself as a potent therapeutic option for autoimmune medical conditions, including systemic lupus erythematosus, owing to its mechanism of action targeting CD20 cells. Rituximab is also known to cause a spectrum of side effects including hematological abnormalities. Acute isolated thrombocytopenia following rituximab is an uncommon occurrence and, when seen, occurs in the presence of underlying hematological malignancies. Its occurrence in autoimmune diseases is rare. Despite this, acute isolated thrombocytopenia in the backdrop of systemic lupus erythematosus is undocumented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A young 36-year-old South Asian female with systemic lupus erythematosus with class IV lupus nephritis poorly responding to standard therapy was initiated on rituximab. Ten days later, she presented with mucocutaneous bleeding and ecchymotic skin lesions. Isolated severe thrombocytopenia was noted with a platelet count of 5\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (150\u2013450). Anticipating life-threatening bleeding, she was given intravenous immunoglobulin, methyl prednisolone, and platelet transfusion considering a spectrum of initial differential diagnosis. Rituximab was also withheld. Though extensively investigated, most investigations were negative. A platelet destructive process was suspected as bone marrow biopsy showed adequate megakaryocytes. Weighing the risk versus benefit, following recovery, she was reinitiated on rituximab. Within 4\u00a0days, she presented again with similar symptoms and severe isolated thrombocytopenia was noted. Rituximab-induced acute thrombocytopenia was considered the working clinical diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case discussion and conclusion<\/jats:title>\n                <jats:p>Rituximab can cause a spectrum of hematological abnormalities, including isolated acute thrombocytopenia. Its occurrence in autoimmune conditions is rare, and its manifestation in systemic lupus erythematosus is undocumented. Its exact etiology is still disputed. Usually considered benign, the platelet numbers tend to show improvement with cessation of therapy. However, in the presence of mucocutaneous bleeding in our patient, we took an aggressive approach to management. Though evidence for corrective therapy is anecdotal, it could be justified on the basis of averting potential catastrophic hemorrhagic manifestations. The spectrum of autoimmune disease that potentially predisposes rituximab to cause thrombocytopenia should be extended to include systemic lupus erythematosus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02950-y","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:05:11Z","timestamp":1625699111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Jevon","family":"Yudhishdran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeyalakshmy","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2353-3964","authenticated-orcid":false,"given":"Mitrakrishnan Rayno","family":"Navinan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sareesh","family":"Bandapatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"5\u20136","key":"2950_CR1","first-page":"244","volume":"64","author":"AJ Scheen","year":"2009","unstructured":"Scheen AJ. International classification of various types of monoclonal antibodies. Rev Med Liege. 2009;64(5\u20136):244\u20137.","journal-title":"Rev Med Liege"},{"key":"2950_CR2","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/trf.14841","volume":"58","author":"J MacIsaac","year":"2018","unstructured":"MacIsaac J, Siddiqi R, Jamula E, Li N, Baker S, Webert KE, et\u00a0al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion. 2018;58:2729.","journal-title":"Transfusion."},{"issue":"5","key":"2950_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","volume":"21","author":"B Jiang","year":"2015","unstructured":"Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol. 2015;21(5):244\u201350.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2950_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddstr.2009.10.001","volume":"6","author":"I Sanz","year":"2009","unstructured":"Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Therapeutic Strategies. 2009;6(1):13\u20139.","journal-title":"Drug Discov Today Therapeutic Strategies."},{"key":"2950_CR5","doi-asserted-by":"crossref","unstructured":"Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg. 2018; 1\u20138.","DOI":"10.1080\/17843286.2018.1521904"},{"key":"2950_CR6","unstructured":"Biogen. Rituxan (rituximab) Label - FDA FDA: FDA; 2012 (cited 2018 October). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf."},{"issue":"8","key":"2950_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2169\/internalmedicine.9628-17","volume":"57","author":"Y Omura","year":"2018","unstructured":"Omura Y, Shimazu H, Takahashi T. Rituximab-induced acute thrombocytopenia in a patient with follicular lymphoma: a case report and review of the literature. Intern Med. 2018;57(8):1151\u20134.","journal-title":"Intern Med"},{"issue":"9","key":"2950_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/07357900802010509","volume":"26","author":"S Dhand","year":"2008","unstructured":"Dhand S, Bahrain H. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Invest. 2008;26(9):913\u20135.","journal-title":"Cancer Invest"},{"issue":"3","key":"2950_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1600-0609.2012.01808.x","volume":"89","author":"TJ Giezen","year":"2012","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, et\u00a0al. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol. 2012;89(3):256\u201366.","journal-title":"Eur J Haematol"},{"issue":"9","key":"2950_CR10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/ard.2004.033100","volume":"64","author":"PD Ziakas","year":"2005","unstructured":"Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis. 2005;64(9):1366\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2950_CR11","doi-asserted-by":"publisher","first-page":"e000078","DOI":"10.1136\/lupus-2014-000078","volume":"2","author":"A Fayyaz","year":"2015","unstructured":"Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et\u00a0al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078.","journal-title":"Lupus Sci Med"},{"issue":"7","key":"2950_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","volume":"45","author":"M Kuwana","year":"2006","unstructured":"Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology. 2006;45(7):851\u20134.","journal-title":"Rheumatology"},{"issue":"12","key":"2950_CR13","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3109\/10428194.2013.784972","volume":"54","author":"H El-Osta","year":"2013","unstructured":"El-Osta H, Nair B. Rituximab-induced acute thrombocytopenia: an underappreciated entity. Leuk Lymphoma. 2013;54(12):2736\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2950_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ajh.21372","volume":"84","author":"R Ram","year":"2009","unstructured":"Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol. 2009;84(4):247\u201350.","journal-title":"Am J Hematol"},{"issue":"24","key":"2950_CR15","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1182\/blood-2012-10-461459","volume":"121","author":"M Morowski","year":"2013","unstructured":"Morowski M, Vogtle T, Kraft P, Kleinschnitz C, Stoll G, Nieswandt B. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood. 2013;121(24):4938\u201347.","journal-title":"Blood"},{"issue":"2","key":"2950_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0975-9727.185012","volume":"7","author":"E Paramjit","year":"2016","unstructured":"Paramjit E, Rao R, Sudhamani S, Roplekar P, Shaffi Z, Roy S. Spectrum of thrombocytopenia: a clinicopathological study with review of the literature. Muller J Med Sci Res. 2016;7(2):121\u20134.","journal-title":"Muller J Med Sci Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:31:08Z","timestamp":1625704268000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2950"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02950-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}